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Dapsone use is frequently associated to hematological side effects such as methemoglobinemia and 
hemolytic anemia, which are related to N-hydroxylation mediated by the P450 enzyme system. The aim 
of the present study was to evaluate the influence of L-arginine supplementation, a precursor for the 
synthesis of nitric oxide, as single or multiple dose regimens on dapsone-induced methemoglobinemia. 
Male Wistar rats were treated with L-arginine at 5, 15, 30, 60 and 180 mg/kg doses (p.o., gavage) in 
single or multiple dose regimens 2 hours prior to dapsone administration (40 mg/kg, i.p.). The effect of 
the nitric oxide synthase inhibitor L-NAME was investigated by treatment with multiple doses of 30 
mg/kg (p.o., gavage) 2 hours before dapsone administration. Blood samples were collected 2 hours after 
dapsone administration. Erythrocytic methemoglobin levels were assayed by spectrophotometry. The 
results showed that multiple dose supplementations with 5 and 15 mg/kg L-arginine reduced dapsone-
induced methemoglobin levels. This effect is mediated by nitric oxide formation, since the reduction in 
methemoglobin levels by L-arginine is blocked by simultaneous administration with L-NAME, a nitric 
oxide synthase inhibitor. 
Uniterms: Dapsone. Methemoglobinemia. L-arginine. Nitric oxide. L-NAME.
O uso da dapsona é frequentemente associado a efeitos adversos hematológicos, como a metemoglobinemia 
e anemia hemolítica, ambos relacionados com a N-hidroxilação mediada pelo sistema P450. O objetivo 
do estudo foi avaliar a influência da suplementação de L-arginina, um precursor da síntese de óxido 
nítrico, administrado em regime de dose única ou múltipla na metemoglobinemia induzida pela dapsona. 
Ratos machos Wistar foram tratados com L-arginina (po, gavagem) em dose única ou múltipla de 5, 15, 
30, 60 e 180 mg/kg 2 horas antes da administração de dapsona (40 mg/kg, ip). O efeito do L-NAME, 
um inibidor de óxido nítrico sintase (NOS), foi avaliado através do tratamento com doses múltiplas de  
30 mg/kg. Amostras de sangue foram coletadas duas horas após a administração de dapsona. A 
concentração de metemoglobina eritrocitária foi analisada por espectrofotometria. Os resultados 
mostraram que a suplementação em dose múltipla de 5 e 15 mg/kg de L-arginina reduziu os níveis de 
metemoglobina induzida pela dapsona. Este efeito é mediado pela formação de óxido nítrico, uma vez 
que a redução nos níveis de metemoglobina pela L-arginina é bloqueada pela administração simultânea 
de L-NAME, um inibidor da óxido nítrico sintase.
Unitermos: Dapsona. Metemoglobinemia. L-arginina. Óxido nítrico. L-NAME.
INTRODUCTION
Dapsone (4,4’-diaminodiphenylsulfone, DDS) is 
a potent antibacterial and anti-inflammatory compound 
and has been clinically used in the treatment of leprosy 
as a component of a multidrug therapy that includes a 
combination of DDS, clofazimine and rifampicin (Katoch 
2002; Walker, Lockwood 2007). The drug is also used 
for the treatment of malaria and Pneumocystic carinii 
pneumonia in patients with acquired immunodeficiency 
N. V. Moraes, M. M. Bergamaschi, M. L. P. Bianchi, J. B. Bragheto, W. R. Malfará, R. H. C. Queiroz88
syndrome (Powell et al., 1967; Mills et al., 1988; Castro 
1998; Tobin-D’Angelo et al., 2004; Nyunt, Plowe 2007).
The major metabolic pathway of DDS is acetylation, 
producing monoacetyldapsone (MADDS). DDS is also 
metabolized by N-hydroxylation mediated by cytochrome 
P450 isozymes CYP2C19, CYP2C9, CYP3A4 and 
CYP2E1 in man, and isozymes CYP2C6/11 and CYP3A1 in 
rats, producing DDS hydroxylamine (DDS-NOH) (Fleming 
et al., 1992; Vage, Svensson, 1994; Mitra et al., 1995; Gill 
et al., 1995; Ganesan et al., 2010). Glucuronidation of 
DDS and DDS-NOH is catalyzed by the enzyme UDP-
glucuronosyltransferase (UGT) allowing its excretion in 
urine and bile (Coleman et al., 1996; Tingle et al., 1997). 
The co-oxidation of DDS-NOH and hemoglobin 
produces nitroso derivatives and methemoglobin, thus 
causing methemoglobinemia and hemolysis (Tingle et 
al., 1990; Coleman, 1995), which are the major dose-
dependent side effects of DDS chronic users (Kaluarachchi 
et al., 2001). MADDS-NOH has been shown to be a more 
potent methemoglobin (metHb) former than DDS-NOH 
in human erythrocytes in vitro (Coleman, Holden, 2004), 
whilst both metabolites present the same potency in rats 
and humans (Vage et al., 1994). 
The reduction of xenobiotic-induced metHb forma-
tion and the mechanisms underlying this effect have been 
widely investigated in the last few years. The various 
attempts to reduce methemoglobinemia have included: 
preventing CYP-mediated oxidative metabolism of xeno-
biotics to hydroxylamines (Coleman et al., 1990; Malfará 
et al., 2002); biochemical attenuation of metHb formation 
with antioxidants (Prussick et al., 1992; Wright et al., 
1996; Dötsch et al., 1998; Wright et al., 1998; Dötsch et 
al., 2000; Tanen et al., 2000; Matteuci et al., 2003; De 
Moraes et al., 2008; Jo et al., 2008); and reduction of 
metHb to hemoglobin by stimulating NADH diaphorase 
or NADPH diaphorase (Dötsch et al., 2000).
L-arginine (ARG), a semi-essential amino acid, is 
the nitrogenous precursor for the synthesis of nitric oxide 
(NO) by a NADPH-dependent NO synthase (NOS) and 
regulates vital metabolic pathways. NO is sufficiently non-
polar to cross membranes without a carrier and is known to 
modulate vasorelaxation and exhibit antioxidant properties 
due to superoxide scavenger and heme oxygenase inductor 
activities (Wood et al., 2008).
In spite of all the evidence pointing to the importance 
of ARG in vital pathways, the role of ARG supplementa-
tion in DDS-induced methemoglobinemia has yet to be 
described in the literature. The aim of the present study 
was to evaluate the role of ARG in single and multiple 
dose regimens in DDS-induced methemoglobinemia. We 
also evaluated whether the effect of ARG on DDS-induced 
methemoglobinemia can be modulated by pretreatment 
with N-nitro-L-arginine methyl ester (L-NAME), a non-
specific NOS inhibitor.
MATERIAL AND METHODS
Dapsone was supplied by FURP (Fundação para o 
Remédio Popular; Guarulhos, Brazil) and L-(+)-arginine 
was supplied by Acros organics (Morris Plains, NJ, USA). 
L-NAME was purchased from Sigma-Aldrich (St. Louis, 
MO, USA). KCN was supplied by Merck (Darmstadt, 
Germany) and K3Fe(CN)6 was supplied by Merck (Rio de 
Janeiro, Brazil). Water was purified with the Milli-Q Plus 
system (Millipore, Bedford, MA, USA).
Experimental study
The experimental study was approved by the Eth-
ics Committee for the Use of Animals of Ribeirão Preto 
Campus, University of São Paulo, Brazil, in accordance 
with the US National Institutes of Health Guide for the 
Care and Use of Laboratory Animals (Protocol number 
06.1.461.53.6). Male Wistar rats (200 ± 20 g) were kept for 
48 hours before the experiment in a room under controlled 
temperature (21-23 °C) and humidity (40-60%) and on a 
12 h light:12 h dark cycle. The animals had free access to 
chow and water throughout the experiment. The animals 
(n = 8 per group) were treated in single or multiple dose 
regimens. ARG was administered orally (p.o. gavage, 
200 μL), dissolved in sterile physiologic saline, whereas 
DDS was dissolved in dimethylsulphoxide (DMSO) and 
administered intraperitoneally (i.p., 200 μL). L-NAME at 
30 mg/kg was administered using a multiple dose regimen 
in the same solution as ARG.
Single dose regimen
The control group received the vehicle of ARG 
(sterile physiological saline) p.o. by gavage two hours 
before the administration of the vehicle used to dissolve 
DDS (DMSO) i.p. The DDS group received 40 mg/kg 
DDS (i.p.) 2 hours after the administration of saline p.o. 
The groups DDS + 5 mg/kg ARG, DDS + 15 mg/kg 
ARG, DDS + 30 mg/kg ARG, DDS + 60 mg/kg ARG, 
DDS + 180 mg/kg ARG received ARG at 5, 15, 30, 60 
and 180 mg/kg doses, respectively, 2 hours before the 
administration of 40 mg/kg DDS. 
Multiple dose regimen
The control group received saline for five days p.o. 
(gavage). On the fifth day, the animals received DMSO 
i.p. 2 hours after saline administration. The DDS group 
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received saline for five days p.o. and 40 mg/kg DDS on 
the fifth day, 2 hours after saline administration. Groups 
DDS + 5 mg/kg ARG, DDS + 15 mg/kg ARG, DDS + 30 
mg/kg ARG, DDS + 60 mg/kg ARG, DDS + 180 mg/kg 
ARG received ARG at 5, 15, 30, 60 and 180 mg/kg doses, 
respectively, for five days. On the fifth day, 2 hours after 
ARG administration, the animals received 40 mg/kg DDS. 
Heparinized blood samples were collected two hours 
after DDS or DMSO administration, in both dose regimens 
(Liquemine 5000 IU, Roche, Rio de Janeiro, Brazil). Met-
hemoglobin levels were determined immediately. 
Methemoglobin assay
Methemoglobin levels relative to hemoglobin levels 
were determined according to the method described by 
Evelyn and Malloy (1938) (modified by Harrison and 
Jollow, 1986). Briefly, an aliquot (200 μL) of heparinized 
blood was added to 10 mL of 0.02 M phosphate buffer pH 
7.8 with 0.05% triton X-100 and then shaken in a mixer 
for 30 seconds. The hemolysate was then fractionated into 
four tubes. Tube 1 (A1) remained with hemolyzed blood. 
An aliquot (50 μL) of 20% K3Fe(CN)6 was added to tubes 
3 (A3) and 4 (A4). An aliquot (50 μL) of 10% KCN was 
then added to tubes 2 (A2) and 4. The absorbance of each 
tube was measured at 635 nm. Methemoglobin levels 
relative to hemoglobin levels were then calculated by the 
following equation: 
 
The initial blood measurement (A1) is referent to 
MetHb and possible interferences. When blood is added 
to KCN (A2), MetHb is converted to cyanomethemo-
globin (CNMetHb) and then possible interferences are 
eliminated because CNMetHb does not absorb at 635 
nm. When blood is added to K3Fe(CN)6 all hemoglobin is 
converted to MetHb, and this measurement refers to total 
MetHb (A3). Finally, blood is added to K3Fe(CN)6 and 
KCN, with all hemoglobin converted to MetHb and then 
to CNMetHb (A4). 
Statistical analysis
GraphPad InStat® software (version 3.01) was used 
for the calculation of means ± standard deviation. ANOVA 
and the Tukey-Kramer post test for multiple comparisons 
(p<0.05) were used to compare groups.
RESULTS
As there is no reference value for methemoglobin 
levels in rats, some preliminary studies were conducted in 
order to evaluate whether ARG or the vehicles could pro-
duce methemoglobinemia. A single dose regimen control 
group was evaluated by administrating sterile physiologi-
cal saline (p.o., 200 μL) and DMSO (i.p., 200 μL). The 
administration of these vehicles resulted in 3.77 ± 0.43% 
methemoglobin formation. In a pilot study, rats were 
treated with 5, 15, 30, 60 and 180 mg/kg of ARG (p.o., 
n = 8) by gavage. Methemoglobin levels were assayed in 
these groups, resulting in 1.70 ± 0.09%, 1.81 ± 0.08%, 
FIGURE 1 - Effect of single dose ARG on methemoglobin levels (%). Animals were treated with ARG at 5, 15, 30, 60 and 
180 mg/kg doses (p.o., gavage) 2 hours prior to the administration of 40 mg/kg of DDS (i.p.). Data expressed as means ± standard 
deviation. *p < 0.05 compared to control group. 
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1.59 ± 0.05%, 1.96 ± 0.08% and 2.03 ± 0.37% of met-
hemoglobin, respectively (data expressed as means ± 
standard deviation). These results showed that ARG alone 
did not produce methemoglobin.
Administration of 40 mg/kg DDS (i.p.) resulted in 
methemoglobin levels of 17.18 ± 1.71% (Figure 1). The 
dose of 40 mg/kg (i.p.) of DDS was known to produce 
methemoglobinemia in rats based on previous studies by 
our group (Malfara et al., 2002; De Moraes et al., 2008; 
Bergamaschi et al., 2011). When ARG was administered in 
a single dose two hours prior to DDS (40 mg/kg) it failed 
to reduce DDS-induced methemoglobinemia (Figure 1).
ARG was also administered at doses 5, 15, 30, 60 
and 180 mg/kg (po), in multiple dose regimens. Methe-
moglobin levels of groups treated with ARG only, in a 
multiple drug regimen, did not produce significant levels 
of methemoglobin (1.88 ± 0.68%; 2.00 ± 0.13%; 2.56 ± 
0.44%; 2.43 ± 0.43% and 1.75 ± 0.76%, respectively), 
as observed for a single dose regimen. Animals treated 
with 5 or 15 mg/kg ARG for 5 days prior to 40 mg/kg 
DDS administration showed a reduction in DDS-induced 
methemoglobinemia, with methemoglobin levels similar 
to the control group. However, higher doses of ARG (30, 
60 and 180 mg/kg) in the multiple dose regimens did not 
inhibit methemoglobin formation (Figure 2).
The effect of L-NAME, a NOS inhibitor, was evalu-
ated in order to understand the mechanisms related to the 
reduction of DDS-induced methemoglobinemia by ARG. 
L-NAME inhibited the reduction in DDS-induced methe-
moglobinemia promoted by ARG, leading to MetHb levels 
comparable to DDS administration alone (Figure 2).
DISCUSSION
The concentration of methemoglobin in erythro-
cytes is regulated by three systems: nicotinamide adenine 
dinucleotide (NADH), nicotinamide adenine dinucleotide 
phosphate (NADPH) and glutathione systems. Methemo-
globin is converted to hemoglobin by the NADH system 
when sufficient NADH-methemoglobin reductase is avail-
able; it contributes to 95% of methemoglobin reduction to 
hemoglobin. The NADPH system reduces methemoglobin 
to hemoglobin through the enzyme NADPH-methemo-
globin reductase and contributes to 5% of methemoglobin 
reduction. Finally, the conversion of reduced glutathione 
to glutathione influences methemoglobin levels by reduc-
ing oxidizing agents (Evelo et al., 1998; Ward, McCarthy, 
1998; Umbreit, 2007).
The standard treatment for methemoglobinemia 
includes infusion with methylene blue, whose action 
depends on the availability of NADPH within the eryth-
rocytes. This therapy requires glucose-6-phosphate dehy-
drogenase (G6PD) optimal activity to produce sufficient 
amounts of NADPH. In G6PD-deficient subjects, methy-
lene blue therapy has been associated with hemolysis and 
methemoglobinemia (Rehman, 2001). Several other sub-
stances have been investigated as alternatives to methylene 
blue therapy. These have included ascorbic acid (Dötsch 
FIGURE 2 - Effect of multiple dose L-arginine (ARG) on methemoglobin level (%). Animals were treated with saline or ARG at 5, 
15, 30, 60 and 180 mg/kg doses (p.o., gavage) or simultaneous gavage of ARG at 5 and 15 mg/kg doses and 30 mg/kg L-NAME for 
five days. On the fifth day, rats were treated with 40 mg/kg DDS (i.p.) 2 hours after ARG administration. Data expressed as means 
± standard deviation. *p < 0.001 compared to the Control group; #p<0.001 when groups treated with L-NAME are compared to 
the respective group without L-NAME.
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et al., 1998), cimetidine (Coleman et al., 1990; Malfará 
et al., 2002), riboflavin (Dötsch et al., 2000), α-lipoic 
acid (Coleman, Taylor, 2003), sodium thiosulfate (Mat-
teucci et al., 2003), ethyl pyruvate (Jo et al., 2008) and 
N-acetylcysteine (Wright et al., 1996; Wright et al., 1998; 
Dötsch et al., 2000; Tanen et al., 2000; De Moraes et al., 
2008). N-acetylcysteine, a precursor of glutathione, used 
in combination with DDS in rats, has shown increased 
methemoglobin levels in these animals compared to rats 
treated with DDS alone. Some authors have suggested 
that glutathione can regenerate DDS-NOH from dapsone 
nitroso derivatives thus resulting in higher methemoglobin 
levels (De Moraes et al., 2008).
Considering the potency of ARG and NO as antioxi-
dant agents, it was proposed that the co-administration of 
ARG and DDS might reduce the methemoglobin levels 
associated to DDS use. The cationic amino acid ARG is 
the precursor for NO biosynthesis mediated by NO syn-
thase. Three isoforms of NO synthase (NOS) occur in a 
number of tissues: neuronal NOS (nNOS); inducible NOS 
(iNOS) located in glia cells, and endothelial NOS (eNOS) 
located in endothelial cells (Palmer et al., 1987; Thomas 
et al., 2008). The iNOS can form much larger amounts 
of NO compared with other isoforms. In many cells and 
pathological conditions the supply of extracellular ARG 
is rate-limiting for NO production (Brunini et al., 2007; 
Thomas et al., 2008).
In the present study, L-NAME administration 
suppressed the reduction in DDS-induced methemoglo-
binemia mediated by 5 mg/kg and 15 mg/kg ARG in 
multiple dose regimens. Considering that L-NAME is 
a non-specific NOS inhibitor, our data suggest that the 
ARG effect on methemoglobin is mediated by NO. NO is 
considered a potent antioxidant agent in vitro and in vivo. 
Its antioxidant activity has been proven by suppressing 
iron-induced generation of hydroxyl radicals (OH) via the 
Fenton reaction, interrupting lipid peroxidation chain reac-
tion, increasing the glutathione antioxidant potency and 
inhibiting cysteine proteases (Chiueh, 1999). On the other 
hand, increased methemoglobin levels are a known toxic 
effect of inhaled NO therapy, commonly used for hypoxic 
neonates. NO can combine with hemoglobin to produce 
nitrosylhemoglobin and thus form methemoglobin by 
oxidation (Weinberger et al., 2001; Hamon et al., 2010). 
Based on our observations, we can hypothesize that lower 
doses of ARG were beneficial to decrease methemoglobin 
levels because of the antioxidant properties of NO. How-
ever, higher doses of ARG do not decrease metHb levels 
because the antioxidant properties of NO are combined to 
its methemoglobinizant effect.
Excess ARG supplementation is also related with the 
production of NG,NG-dimethyl-L-arginine (ADMA) which 
is a NOS inhibitor (Masuda et al. 2002). This metabolite 
can convert NO to a superoxide generator (Thomas et al., 
2008). This may explain why NO is beneficial to DDS-
induced methemoglobinemia at low ARG concentrations 
yet deleterious when excess ARG supplementation is 
administered to rats in multiple dose regimens. 
NO also produces inhibitory effects in cytochrome 
P450 mediated drug metabolism. It is known that NO 
forms complexes with the catalytic center of P450 en-
zymes which results in a decrease in enzymatic activities 
of rat microsomes (Khatsenko et al. 1993). The inhibi-
tory effects of NO are rapid, concentration-dependent 
and mainly in CYP 2C11 > 2B1/2 > 2E1 = 3A2 > 1A1/2 
(Vuppugalla, Mehvar 2004a, 2004b). If NO had inhibited 
DDS oxidative metabolism, animals treated with higher 
ARG concentration would present lower metHb levels. 
However, our results showed that the reduction in MetHb 
levels by ARG is observed only when animals are treated 
with multiple doses of 5 and 15 mg/kg ARG. Thus, CYP 
inhibition by NO does not seem to explain the reduction 
in MetHb levels. 
In conclusion, ARG reduces DDS-induced methe-
moglobinemia in rats when low doses (5 and 15 mg/kg) 
are administered as a multiple dose regimen. The effect 
can be blocked by the simultaneous administration of 
L-NAME (a NOS inhibitor). Thus, we can conclude that 
ARG supplementation can be an effective reducing agent 
for chronic treatment of DDS-induced methemoglobin-
emia and that its effect is mediated by NO.
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